The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
21-Apr-15
$NA
Target:
Tate & Lyle plc
Acquiror:
Archer Daniels Midland Company
Advised Tate & Lyle plc, a leading provider of ingredients and solutions to the food, beverage and other industries, on the re-alignment of Eaststarch C.V., its 50:50 corn wet milling joint venture in Europe with Archer Daniels Midland Company
11-Aug-14
$NA
Target:
MannKind Corporation
Acquiror:
Sanofi
Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.
05-Aug-14
$1.3 billion
Target:
Siemens Health Services
Acquiror:
Cerner Corporation
Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.
18-Feb-14
$25.1 billion
Target:
Forest Laboratories Inc.
Acquiror:
Actavis plc
Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.
04-Dec-13
$850 million
Target:
Megapolis Distribution
Acquiror:
Japan Tobacco Inc
Advised Japan Tobacco Inc in connection with the acquisition of a minority stake in Megapolis Distribution B.V., Russia’s leading tobacco distributor
20-May-13
$8.5 billion
Target:
Warner Chilcott, plc
Acquiror:
Actavis, Inc.
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
26-Apr-13
$NA
Target:
Yakult Honsha
Acquiror:
Danone
Advised Danone, a world leading food company, on its business and capital alliance with Yakult Honsha, the largest probiotic dairy product manufacturer in Japan
17-Oct-12
$2.6 billion
Target:
Cymer, Inc.
Acquiror:
ASML Holding NV
Advised ASML Holding NV, a leading provider of lithography systems for the semiconductor industry, on its acquisition of Cymer, Inc., a leading supplier of lithography light sources used by chipmakers to manufacture advanced semiconductor devices
01-Aug-12
$4.0 billion
Target:
Mediclinic International Limited
Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa
09-Jul-12
$4.7 billion
Target:
ASML Holding NV (minority stake)
Acquiror:
Customers including Intel Corporation, TSMC and Samsung Electronics
Advised the Supervisory Board of ASML on the establishment of a Customer Co-Investment Program including the issue of 23% equity stake and $1.7 billion of R&D funding
06-Jul-12
$730 million
Target:
WMF Württembergische Metallwarenfabrik AG
Acquiror:
Kohlberg Kravis Roberts & Co. L.P.
Provided fairness opinion to the Executive Management Board of WMF in connection with the voluntary public takeover offer by Finedining Capital GmbH, a holding company in the possession of funds managed by Kohlberg Kravis Roberts & Co. L.P.
16-Jan-12
$428 million
Target:
Robert Wiseman Dairies PLC
Acquiror:
Unternehmensgruppe Theo Müller
Advised Robert Wiseman Dairies PLC, the UK’s largest processor of fresh milk, on a recommended offer from Unternehmensgruppe Theo Müller S.e.c.s.
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
04-Dec-09
$NA
Target:
Verivox Holding Limited
Acquiror:
Oakley Capital Private Equity LP
Advised the shareholders of Verivox Holdings Limited, comprising Independent News & Media plc and the founders and joint CEOs of Verivox, on the sale of 51% in Verivox, Germany’s leading price comparison website for energy and telecommunications services, to Oakley Capital Private Equity
09-Nov-09
$327 million
Target:
Enzon Pharmaceuticals, Inc.
Acquiror:
Sigma-Tau Pharmaceuticals
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
12-Mar-09
$46.9 billion
Target:
Genentech, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
05-Aug-08
$NA
Target:
BARTEC Group
Acquiror:
Capvis
Advised Capvis, a leading Swiss private equity firm, on its acquisition of the BARTEC Group, a leading European provider of industrial safety technology, from Allianz Capital Partners, the captive private equity arm of Allianz AG, and the Barlian family (founding family)
22-Jan-08
$3.4 billion
Target:
Ventana Medical Systems, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment
19-Dec-06
$270 million
Target:
Brion Technologies, Inc.
Acquiror:
ASML Holding N.V.
Advised ASML Holding N.V., a leading provider of lithography systems for the semiconductor industry, on its acquisition of Brion Technologies, Inc.
18-Dec-06
$NA
Target:
InBev SA
Acquiror:
Mr. Wolfgang Dinkelacker
Advised InBev SA, the world's largest brewery, on the sale of German regional brewery Dinkelacker-Schwaben Bräu KG
24-Mar-06
$21.2 billion
Target:
Schering AG
Acquiror:
Bayer AG
Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany
Pages
- « first
- ‹ previous
- 1
- 2
- 3